



HCV Directly Acting Antivirals & RBV

Charts revised January 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED/SOF, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table with columns for drug classes (Antidepressants, Antidiabetics, Antifungals) and antivirals (DCV, EBR/GZR, GLP/PIB, LED/SOF, OBV/PTV/r + DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV). Rows list various drugs with colored symbols indicating interaction levels.

Table with columns for drug classes (Antihistamines, Antimigraine Agents, Antiprotozoals, Antipsychotics/Neuroleptics) and antivirals (DCV, EBR/GZR, GLP/PIB, LED/SOF, OBV/PTV/r + DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, RBV). Rows list various drugs with colored symbols indicating interaction levels.

For personal use only. Not for distribution.

Key to symbols

Key to symbols table with 4 rows: Red circle (no coadministration), Orange square (clinical interaction), Yellow triangle (weak interaction), Green diamond (no interaction).

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice.



HCV Directly Acting Antivirals & RBV

Charts revised January 2020. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

DCV, Daclatasvir; EBR/GZR, Elbasvir/Grazoprevir; GLP/PIB, Glecaprevir/Pibrentasvir; LED, Ledipasvir; OBV/PTV/r + DSV, Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir; SMV, Simeprevir; SOF, Sofosbuvir; VEL, Velpatasvir; VOX, Voxilaprevir; RBV, Ribavirin.

Table listing drug interactions for Erectile Dysfunction Agents, Gastrointestinal Agents, HCC Therapies, and Hepatitis Drugs. Columns include DCV, EBR/GZR, GLP/PIB, LED/SOF, OBV/PTV/r, OBV/PTV/r + DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, and RBV. Symbols indicate interaction levels.

Table listing drug interactions for Herbals/Supplements/Vitamins, HIV Drugs, and Protease Inhibitors. Columns include DCV, EBR/GZR, GLP/PIB, LED/SOF, OBV/PTV/r, OBV/PTV/r + DSV, SMV, SOF, SOF/VEL, SOF/VEL/VOX, and RBV. Symbols indicate interaction levels.

For personal use only. Not for distribution.

Key to symbols

Legend for symbols: Red diamond (no coadministration), Orange square (clinical interaction), Yellow triangle (weak interaction), Green diamond (no interaction).

Notes

- Further information is available at www.hep-druginteractions.org
Predicted interactions are based on known metabolic pathways and routes of clearance.
Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice.



